Category: Market Commentary

Altimmune Inc. (ALT) stock reacts opposite to the Phase 1 Clinical Trial of ALT-801 data announced by the company. In the 12-week trials, the mean weight loss of 10.3% was achieved in subjects receiving a 1.8 mg dose.  The biopharmaceutical firm, Altimmune Inc. (ALT), has just updated its ongoing Phase 1 trial results of pemvidutide (formerly known as ALT-801). The results from the 12-week study shows positive data as pemvidutide was well-tolerated without the need for dose titration. Surprisingly, ALT stock is significantly down as of trading on September 28, 2021. The share price has dropped over 30% since the last trading day. Altimmune

Alfi Inc. (ALF) stock prices were up by 16.29% shortly after market trading commenced on September 28th 2021. This brought the price per share up to USD$8.22 early on in the trading day. ALF Stock’s Collaboration September 28th 2021 saw ALF stock announce its partnership with Vistar Media, a major programmatic exchange. As per the agreement, advertisers and agencies will be provided with programmatic access to the company’s impactful inventory. Complex delivery across the company’s campaigns will also be enabled. The company will be joining the programmatic exchange through its partner’s supply side platform. This will allow advertisers to purchase

Digital Brands Group Inc. (DBGI) stock prices were up by 43.05% shortly after market trading commenced on September 28th, 2021. This brought the price per share up to USD$4.22 early on in the trading day. DBGI Stock Announces Guidance September 28th 2021 saw DBGI stock announce the increase of its initial 2022 revenue guidance. The new forecast ranges from USD$37.5 million to USD$42.5 million. This represents a 350% increase from the revenue expectations from fiscal 2021. Furthermore, the company expects positive EBITDA for 2022. These developments reflect the power the company’s brand portfolio, with the possibility to further improve following

Sonoma Pharmaceuticals, Inc. (SNOA) stock made a swift move as the buying volume increased following the Amazon.com business announcement. In the pre-market on September 28, 2021, SNOA stock had already soared above 70%.  The global healthcare leader in stabilized hypochlorous acid (HOCl) products, Sonoma Pharmaceuticals, Inc. (SNOA) intends to invest in Amazon’s e-commerce business. The company will make an over-the-counter (OTC) consumer launch on Amazon.com in the United States and Europe. Investors have really appreciated the development of SNOA. Entering the e-commerce business means that Sonoma has taken a competitive advantage as they consider it a potential market. Sonoma Pharmaceuticals has decided

Farmmi, Inc. (FAMI) stock popped high today following the announcement of additional multi-Product sales win. FAMI stock price saw a push of 17.57% to reach $0.27 a share at the time of this writing. The stock was also green in the previous trade and went high by 14.09% at closing. Farmmi, Inc operates by selling agricultural products in China, United States, and in many countries across the globe. Let’s dig in to explore more about this stock. What’s Happening? According to a recent announcement, FAMI stock’s subsidiary Zhejiang Forest Food Co., Ltd has received an additional multi-product for export to

Scientific Games Corp. (SGMC) stock prices were up by 2.05% as of the market closing on September 27th 2021. This brought the price per share up to USD$82.95 at the end of the trading day. Subsequent premarket fluctuations have seen the stock fall by 6.69%, bringing it down to USD$88.50. SGMC Stock Divests OpenBet September 27th 2021 saw SGMC stock announce having entered into a definitive agreement to sell its Sports Betting business, Openbet. The agreement was signed with Endeavor Group Holdings, a global sports and entertainment company. The transaction will be conducted in cash and stock valued at USD$1.2

ZIOPHARM Oncology Inc. (ZIOP) stock prices were up by 4.43% as of the market closing on September 27th 2021. This brought the price per share up to USD$2.12 at the end of the trading day. Subsequent premarket fluctuations have seen the stock fall by 18.40%, bringing it down to USD$1.73. ZIOP Stock’s Restructuring September 27th 2021 saw ZIOP stock announce its restructuring program, wherein roughly 60 positions within the company have been eliminated. This development was in the interest of advancing its TCR program. This will be facilitated by the expected extension of the company’s cash runway into the first

ASLAN Pharmaceuticals Limited (ASLN) has experienced a decrease of 28.31% in the premarket after ASLN announces positive data establishing proof of concept for ASLAN004 in Atopic Dermatitis. However, the last trading session closed at $3.25 with an increase of 0.31%. Positive Data Establishing Proof of Concept by ASLN On 27th September 2021, ASLN announced that ASLAN004 had good topline findings from its placebo-controlled, 8-week, multiple-ascending-dose Phase 1 trial. ASLAN004, a possible first-in-class monoclonal antibody targeting the IL-13 receptor, was well tolerated in all dosages. The study’s findings demonstrate proof of concept and indicate ASLAN004’s potential as a differentiated, new therapy

U.S. Energy Corp. (USEG) saw a push of 7.64% in the premarket. However, the last trading session closed at $4.71 with an incline of 1.07%. Second Quarter 2021 Financial Results USEG announced second-quarter 2021 financial results on 12th August 2021. Firstly, sales of oil and natural gas generated $1.7 million in the second quarter of 2021. A rise in oil production volumes and an improvement in realized commodity prices accounted for the majority of the income change. Secondly, during the quarter, revenue from oil production accounted for 91 percent of our total revenue. The Company owns and runs properties that

VolitionRX Ltd. (VNRX) stock prices were up by 1.56% as of the market closing on September 24th 2021. This brought the price per share up to USD$3.25 at the end of the trading day. Nu.Q Vet Cancer Screening Test VNRX stock reported being engaged in multiple epigenetic projects that are based on its proprietary Nu.QTM platform. The platform has been used to develop numerous blood-based clinical assays. The beta launch of Nu.Q Vet Cancer Screening Test has commenced the generation of revenues. Management is actively participating in discussions with various small and large companies that focus on veterinary products and